Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Volastra Therapeutics has raised $30.1M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
Volastra Therapeutics's investors include B Capital, ARCH Venture Partners, Eli Lilly, Catalio Capital Management, Vida Ventures.
Volastra Therapeutics is headquartered in New York, United States.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Volastra Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Volastra Therapeutics — Funding & Investors." VCBacked, September 23, 2025, https://www.vcbacked.co/company/volastra-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Volastra Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/volastra-therapeutics
{{cite web |title=Volastra Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/volastra-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated